Aethlon Medical (NASDAQ:AEMD) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research note issued on Wednesday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright reduced their price target on shares of Aethlon Medical from $23.00 to $10.00 and set a “buy” rating on the stock in a report on Monday, March 4th.

Aethlon Medical Price Performance

Shares of AEMD stock opened at $1.68 on Wednesday. The company has a market capitalization of $4.40 million, a price-to-earnings ratio of -0.34 and a beta of 1.89. The company’s fifty day moving average price is $1.74 and its 200-day moving average price is $1.86. Aethlon Medical has a one year low of $1.40 and a one year high of $7.20.

Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings results on Wednesday, February 14th. The medical equipment provider reported ($1.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.14). Equities research analysts expect that Aethlon Medical will post -4.98 earnings per share for the current fiscal year.

Institutional Trading of Aethlon Medical

A number of large investors have recently made changes to their positions in AEMD. HRT Financial LP bought a new stake in shares of Aethlon Medical in the 4th quarter worth about $28,000. Renaissance Technologies LLC increased its holdings in shares of Aethlon Medical by 61.4% in the 4th quarter. Renaissance Technologies LLC now owns 100,600 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 38,264 shares during the last quarter. Two Sigma Investments LP bought a new stake in shares of Aethlon Medical in the 3rd quarter worth about $32,000. Jane Street Group LLC increased its holdings in shares of Aethlon Medical by 895.7% in the 4th quarter. Jane Street Group LLC now owns 140,245 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 126,160 shares during the last quarter. Finally, Citadel Advisors LLC bought a new stake in shares of Aethlon Medical in the 3rd quarter worth about $72,000. 1.99% of the stock is currently owned by institutional investors.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system.